ストックスクリーナーアプリを入手
270.56
0.21%
-0.56
Ascendis Pharma A S (ASND) 最新ニュース
Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine - Yahoo Finance
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript - AOL.com
Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress? - Yahoo Finance
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Strong-Buy at BMO Capital Markets - MarketBeat
Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced? - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis a new outperform at BMO on TransCon platform growth - Seeking Alpha
Penn Series Small Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
BMO initiates Ascendis Pharma stock coverage with outperform rating By Investing.com - Investing.com Nigeria
BMO initiates Ascendis Pharma stock coverage with outperform rating - Investing.com
BMO Capital Initiates Ascendis Pharma at Outperform - marketscreener.com
Ascendis Pharma (ASND) Reports Positive Phase 2 Achondroplasia Data As Pivotal Trial Enrollment Ends - Sahm
Why Is Nasdaq Watching Ascendis Pharma (NASDAQ:ASND) Endocrine Drugs? - Kalkine Media
Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Purchases 2,000 Shares of Stock - MarketBeat
Ascendis Pharma (NASDAQ: ASND) director adds 2,000 shares - Stock Titan
Ascendis Pharma director Jean-Jacques Bienaime buys USD 492,079 of common shares - Bitget
Ascendis Pharma A/S (ASND) Stock Analysis: Healthcare Innovator with a 25% Upside Potential - DirectorsTalk Interviews
symbol__ Stock Quote Price and Forecast - CNN
Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $275 to $360 - Moomoo
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen - MarketBeat
Allspring Emerging Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth - simplywall.st
Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS - MarketBeat
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call - Sahm
Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital. - Pluang
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says - marketscreener.com
RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating - marketscreener.com
Ascendis Pharma doubles sales, significantly boosting profit - medwatch.com
Ascendis Pharma AS earnings beat by €1.32, revenue topped estimates - Investing.com Nigeria
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Re - GuruFocus
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ... - Yahoo Finance
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength By Investing.com - Investing.com South Africa
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength - Investing.com Nigeria
Artisan Partners (ASND holder) discloses 2.63M Ascendis Pharma shares in 13G/A - Stock Titan
Ascendis Pharma's Long-Term Potential Intact, Wedbush Says - marketscreener.com
Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost - Quiver Quantitative
Ascendis Pharma A/S Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Ascendis Pharma tops Q2 2026 estimates as launches gain - Investing.com
ASND: Q2 revenue more than doubled year-over-year, fueled by strong TransCon product demand and robust launches - TradingView
Ascendis Pharma A/S reports results for the quarter ended June 30Earnings Summary - TradingView
Ascendis Pharma (ASND) posts Q2 2026 profit on revenue surge and PRV sale - Stock Titan
Ascendis Pharma: Product Revenue Surges 105% To €315 Million As Adjusted Operating Profit Turns Positive - Pulse 2.0
Ascendis Pharma A/S Q2 2026 Earnings Call Transcript - MarketBeat
Ascendis Pharma's Q2 Adjusted Earnings, Revenue Rise - marketscreener.com
Ascendis Pharma (ASND) posts €836M H1 profit and redeems $575M converts - Stock Titan
Ascendis Pharma swings to Q2 profit on revenue doubling, PRV sale - TradingView
Earnings Flash (ASND) Ascendis Pharma Posts Q2 Non-IFRS EPS 0.90 Euros, vs. FactSet Est of 1.80 Euros - marketscreener.com
Ascendis Pharma Reports Second Quarter 2026 Financial Results - The Manila Times
Ascendis Pharma Reports More Than 220 U.S. YUVIWEL Enrollments - Stock Titan
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ... By GuruFocus - Investing.com Canada
Ascendis Pharma (ASND) issues 15,060 staff warrants at $254.57 strike price - Stock Titan
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today - Benzinga
Ascendis Pharma A/S expected to post earnings of €1.38 a shareEarnings Preview - TradingView
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup - ChartMill
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275 - 富途牛牛
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):